Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 12 of 12 entries
View as:

Open Label Trial Studying the Safety and Effectiveness of ILUVIEN® (190μg) in Children and Adolescents, Who Have Recurrent Non-infectious Uveitis Affecting the Posterior Segment of the Eye.

Phase: N/A Priority: Normal
NCT ID: NCT06539481 Org: User:
Start: 08/31/24 End: 10/31/28 Due: 10/31/29

Phase 4 IOP Signals Associated With ILUVIEN®

Phase: N/A Priority: Normal
NCT ID: NCT02424019 Org: User:
Start: 05/06/15 End: 07/31/20 Due: 07/31/21

Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis

Phase: N/A Priority: Normal
NCT ID: NCT05322070 Org: User:
Start: 06/06/22 End: 11/30/25 Due: 11/30/26

Observational Study to Assess the Effect of Iluvien® in DME Patients Insufficiently Responsive to Available Therapies

Phase: N/A Priority: Normal
NCT ID: NCT02080091 Org: User:
Start: 12/31/13 End: 04/30/15 Due: 04/30/16

Fluocinolone Acetonide Intravitreal Inserts in Geographic Atrophy

Phase: N/A Priority: Normal
NCT ID: NCT00695318 Org: User:
Start: 12/31/08 End: - Due: -

Pharmacokinetic and Efficacy Study of Fluocinolone Acetonide Inserts in Patients With Diabetic Macular Edema

Phase: N/A Priority: Normal
NCT ID: NCT00490815 Org: User:
Start: 08/31/07 End: 04/30/11 Due: 04/30/12

Iluvien Registry Safety Study

Phase: N/A Priority: Normal
NCT ID: NCT01998412 Org: User:
Start: 12/31/13 End: 01/31/20 Due: 01/31/21

Fluocinolone Acetonide Implant Compared to Sham Injection in Patients With Diabetic Macular Edema

Phase: N/A Priority: Normal
NCT ID: NCT00344968 Org: User:
Start: 09/30/07 End: 12/31/10 Due: 12/31/11

Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study

Phase: N/A Priority: Normal
NCT ID: NCT01304706 Org: User:
Start: 04/30/11 End: - Due: -

Fluocinolone Acetonide Intravitreal Inserts for Vein Occlusion in Retina

Phase: N/A Priority: Normal
NCT ID: NCT00770770 Org: User:
Start: 05/31/09 End: - Due: -

A Non-Randomized, Open-Label, Single Center Phase 4 Study of the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (Laser, Anti-VEGF) With or Without Intravitreal Corticosteroid Therapy

Phase: N/A Priority: Normal
NCT ID: NCT02472366 Org: User:
Start: 01/31/14 End: 05/31/15 Due: 05/31/16

A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)

Phase: N/A Priority: Normal
NCT ID: NCT04469595 Org: User:
Start: 08/31/20 End: 12/31/24 Due: 12/31/25